{"id":"W2233483325","doi":"10.1016/s1470-2045(15)00515-x","title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Cancer Research UK; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; F. Hoffmann-La Roche; Astellas Pharma US; Pfizer; Durham University; Abbott Laboratories","keywords":"Sunitinib; Everolimus; Renal cell carcinoma; Medicine; Oncology; Open label; Internal medicine; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001946562,0.002078051,0.003336008,0.0003449119,0.0003973328,0.001193636,0.0007601101,0.001803431,0.006318668],"category_scores_gemma":[0.001668527,0.000723697,0.002631261,0.0003709292,0.001074042,0.00171878,0.0004812938,0.003320699,0.000961675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008113768,"about_ca_system_score_gemma":0.0008268665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009177515,"about_ca_topic_score_gemma":0.002806541,"domain_scores_codex":[0.9992437,0.0004430217,0.00004059594,0.0001216705,0.00004644149,0.0001045432],"domain_scores_gemma":[0.9993054,0.0002121159,0.0001606441,0.00005615942,0.00004112475,0.0002245017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.982899,0.002083391,0.0004307713,0.0006372192,0.00133059,0.00003720132,0.00005002978,0.0005006198,0.001233072,0.0001087713,0.0007096287,0.009979674],"study_design_scores_gemma":[0.9554276,0.04112717,0.001337926,0.00003415839,0.0005628953,0.00004510026,0.00002864034,0.0003494713,0.0002013917,0.0002058939,0.0006641513,0.00001557568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859844,0.007220098,0.0005960468,0.0009879906,0.0007735297,0.001553582,0.000927498,0.000107318,0.001849591],"genre_scores_gemma":[0.9880577,0.003175269,0.00111899,0.001044511,0.0003492791,0.001450866,0.0009872894,0.00002543259,0.003790732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006318668,"threshold_uncertainty_score":0.02113801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0994465300835262,"score_gpt":0.3632002380958994,"score_spread":0.2637537080123732,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}